Concepedia

Marion Carrigan

MC

Statistics

Publications

4

Citations

598

H-Index

4

Active since

2016

Affiliations

Georgetown University(Current)

Dana-Farber Cancer Institute

Merck & Co., Inc., Rahway, NJ, USA (United States)

Vall d'Hebron Institute of Oncology

Marion Carrigan is an author at Georgetown University specializing in cancer therapeutics, oncology, and radiation oncology.

Top concepts

Publications per year

2016–2018

4

Publications

4

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud et al. · Journal of Clinical Oncology · 2017 · 504 citations

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud et al. · Obstetrical & Gynecological Survey · 2018 · 44 citations

, , +18

Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study.

Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud et al. · Journal of Clinical Oncology · 2016 · 27 citations

, , +13

P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Greg J. Riely, Rina Hui, David P. Carbone et al. · Journal of Thoracic Oncology · 2018 · 23 citations

, , +8

1–4 of 4